Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

VitaFlow LIBERTY Europe

28. september 2026 oppdatert av: Shanghai MicroPort CardioFlow Medtech Co., Ltd.

VitaFlow Liberty™ Transkateter aortaklaffsystem Klinisk oppfølgingsstudie etter markedsføring

This is a prospective, single-arm, multi-center, observational, post-market clinical investigation to document the clinical safety and performance of MicroPort CardioFlow VitaFlow Liberty™ Transcatheter Aortic Valve System in the routine practice for the treatment of severe aortic valve stenosis. The primary endpoint is the composite rate of all-cause mortality and stroke with disability at 12 months.

Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.

Studieoversikt

Status

Rekruttering

Studietype

Observasjonsmessig

Registrering (Antatt)

222

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Galway, Irland
        • Rekruttering
        • Galway University Hospital
        • Ta kontakt med:
          • Darren Mylotte, MD
      • Castel Volturno, Italia
        • Rekruttering
        • Pineta Grande Hospital
        • Ta kontakt med:
      • Pisa, Italia
        • Rekruttering
        • Ospedale Cisanello
        • Ta kontakt med:
      • Potenza, Italia
        • Rekruttering
        • Azienda Ospedaliera Regionale -S.Carlo
        • Ta kontakt med:
      • Carnaxide, Portugal
        • Rekruttering
        • Hospital de Santa Cruz
        • Ta kontakt med:
      • A Coruña, Spania
        • Rekruttering
        • Hospital Universitario de a Coruna
        • Ta kontakt med:
      • Madrid, Spania
      • Valladolid, Spania
      • Lucerne, Sveits
        • Rekruttering
        • Luzerner Kantonsspital | Herzzentrum
        • Ta kontakt med:
          • Dr.Stefan Toggweiler
          • Telefonnummer: 0412051111
          • E-post: ifo@luks.ch

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients with symptomatic, severe calcified aortic stenosis who are at high surgical risk.

Beskrivelse

Inclusion Criteria:

  1. Subjects of age≥ 18 years
  2. Subjects with severe, symptomatic, calcific aortic stenosis who are considered at high risk for surgical aortic valve replacement (AVR).
  3. Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow up requirements.

Exclusion Criteria:

  1. Pre-existing mechanical heart valve in aortic position
  2. A known hypersensitivity or contraindication to all anticoagulation /antiplatelet regimens (or inability to be anticoagulated for the index procedure), to nickel or titanium, to nitinol, to dairy products, to polyethylene terephthalate (PET) or contrast media
  3. Ongoing sepsis, including active endocarditis
  4. Anatomically not suitable for the VitaFlow Liberty TAV system
  5. LVEF<20%
  6. Estimated life expectancy of less than 12 months
  7. Any medical, social or psychological condition that in the opinion of the Heart Team precludes the subject from receiving transcatheter aortic valve replacement
  8. Currently participating in another drug or device trial (excluding registries) for which the primary endpoint has not been assessed
  9. Inability to comply with the clinical investigation follow-up or other clinical investigation requirements
  10. Patients temporally unable to provide written informed consent (e. g. unconscious emergency patients)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Enarms klinisk undersøkelse

Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System.

Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Composite rate of all-cause mortality and stroke with disability
Tidsramme: 12 months post procedure

Composite rate of all-cause mortality and stroke with disability

12 months post procedure

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety outcomes defined by VARC3
Tidsramme: 30 days, 12 months, and 2-5 years post procedure

Rate of all-cause mortality, myocardial infarction, stroke, implanted related new and/or worsen conduction disturbances and arrhythmias, new permanent pacemaker implantation, procedure-related or valve-related hospitalization defined by VARC 3.

30 days, 12 months, and 2-5 years post procedure
Safety outcomes defined by VARC3
Tidsramme: 30 days and 12 months post procedure

Rate of type 2-4 bleeding, major vascular and access-related complications, acute kidney injury (stage 2-4) defined by VARC 3

30 days and 12 months post procedure
Safety outcomes defined by VARC3
Tidsramme: acute procedure (within 24 hours)

Rate of other acute procedural and technical valve related complications: conversion to surgery; unplanned use of mechanical circulatory support; implantation of multiple (>1) transcatheter valves during the index hospitalization; valve mal-position

acute procedure (within 24 hours)
Device success
Tidsramme: 30 days post implantation

Device success defined by VARC 3

30 days post implantation
Device early safety
Tidsramme: 30 days post implantation

Device early safety defined by VARC 3

30 days post implantation
Bioprosthesis haemodynamic function
Tidsramme: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

Bioprosthesis haemodynamic function (assessed by echocardiography) including effective orifice area (cm2).

Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
Bioprosthesis haemodynamic function
Tidsramme: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

Bioprosthesis haemodynamic function (assessed by echocardiography) including mean transvalvular gradient (mmHg).

Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
Bioprosthesis haemodynamic function
Tidsramme: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

Bioprosthesis haemodynamic function (assessed by echocardiography) including aortic regurgitation (paravalvular, central and total).

Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
Bioprosthetic valve dysfunction
Tidsramme: 12 months and 2-5 years post procedure

Moderate or severe haemodynamic valve deterioration defined by VARC3

12 months and 2-5 years post procedure
Bioprosthetic valve dysfunction
Tidsramme: 12 months and 2-5 years post procedure

Bioprosthetic valve failure defined by VARC3

12 months and 2-5 years post procedure
Bioprosthetic valve dysfunction
Tidsramme: 12 months and 2-5 years post procedure

Clinically significant valve thrombosis defined by VARC3

12 months and 2-5 years post procedure
NYHA Classification
Tidsramme: From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure

Changes in cardiac function at discharge, 30 days and 12 months and 2-5 years post implantation according to the NYHA Classification Scheme compared to baseline

From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure
Rate of Alwide Plus Balloon Catheter pre-dilation success
Tidsramme: During procedure

Defined as successful access, delivery and dilation the aortic valve, and retrieval for the AlwideTM Plus balloon catheter

During procedure
Alwide Plus Balloon Catheter related adverse-event
Tidsramme: Discharge
Discharge
Predictors for the permanent pacemaker implantation
Tidsramme: Baseline or intraprocedure

Including but not limited to pre-existing conduction disturbance, implant depth, LVOT calcium volume , post-dilatation

Baseline or intraprocedure

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Darren Mylotte, MD, Galway University Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. mai 2025

Primær fullføring (Antatt)

6. juni 2028

Studiet fullført (Antatt)

1. juni 2033

Datoer for studieregistrering

Først innsendt

21. juli 2024

Først innsendt som oppfylte QC-kriteriene

30. juli 2024

Først lagt ut (Faktiske)

2. august 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. desember 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere